Wells Fargo Upgrades Nevro to Overweight, Announces $116 Price Target
Wells Fargo analyst Lawrence Biegelsen upgrades Nevro (NYSE:NVRO) from Equal-Weight to Overweight and announces $116 price target.
10 Biggest Price Target Changes For Tuesday
Craig-Hallum cut Zix Corporation (NASDAQ: ZIXI) price target from $12 to $8.5. Zix shares fell 0.4% to $8.48 in pre-market trading.
Truist Securities Downgrades Nevro to Hold, Lowers Price Target to $105
Truist Securities analyst Kaila Krum downgrades Nevro (NYSE:NVRO) from Buy to Hold and lowers the price target from $165 to $105.
Wells Fargo Maintains Equal-Weight on Nevro, Lowers Price Target to $116
Wells Fargo analyst Lawrence Biegelsen maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $122 to $116.
SVB Leerink Maintains Outperform on Nevro, Lowers Price Target to $128
SVB Leerink analyst Danielle Antalffy maintains Nevro (NYSE:NVRO) with a Outperform and lowers the price target from $147 to $128.
Nevro: Q3 Earnings Insights
Nevro (NYSE:NVRO) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Nevro reported in-line EPS of $-0.87 versus an estimate of $-0.87, which did not surprise analysts.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Preview: Nevro’s Earnings
Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Nevro will likely report an Earnings Per Share (EPS) of $-0.87
OTR Global Downgrades Nevro to Mixed
OTR Global downgrades Nevro (NYSE:NVRO) from Positive to Mixed.